An immunotherapy antibody targeting CD4 T-cells anergy in HIV and cancer

CD4 T lymphocytes are immune cells whose activation is crucial in immune responses to promote and regulate the functions of other cells, including monocytes, macrophages, NK cells[1, 2, 3], B lymphocytes [4] and cytotoxic CD8 T cells [5]. However, CD4 T cells can also become inactive while remaining alive [6], acquiring a status termed anergy, in which they proliferate less and produce less cytokines (the molecular messengers used to communicate with other immune cells). CD4 T cell anergy is a physiological phenomenon that plays a role in establishing tolerance to markers of self and prevents auto-immune responses [7].

In addition, CD4 T cell anergy also occurs in pathological conditions, preventing necessary immune responses and therefore contributing to the establishment of chronic diseases associated with immune deficiencies. Sometimes accompanied by CD4 T cell depletion, anergy has been observed in several infectious contexts, including bacterial [8, 9, 10], viral [11, 12, 13, 14, 15] and parasitic infections [16]. Anergic CD4 T cells have also been observed in a number of solid and blood cancers arguing that their unresponsive state may hinder the establishment of an efficient anti-tumor immune response [17: Colorectal cancer, Metastatic cancers, Review T cell anergy, Pancreatic cancer]. Reverting the anergic status of CD4 T cells has therefore emerged as an attractive therapeutic means to restore functional immunity in these pathological contexts.

Diaccurate is developing a sole-in-class immunotherapy antibody that blocks the pathogenic activity of PLA2G1B, a blood soluble enzyme involved in CD4 T cell anergy in HIV-infected patients. DIACC1010 is currently in early preclinical development in HIV and discovery stage in oncology.

Understanding CD4 T cell anergy in HIV-infected patients

The immune deficiency that characterizes most HIV-infected patients is intimately linked to dysfunctional CD4 T lymphocytes. Fewer than 10% of circulating CD4 T cells are effectively infected by the virus [18] and yet the overall numbers of these cells progressively decline and the remaining cells display profound functional defects [19]. Over the years, research by Prof. Jacques Thèze and colleagues has largely contributed to characterizing these CD4 T cell dysfunctions. In particular, they demonstrated that the cells became unresponsive to stimulation by the IL-7 cytokine [20, 21, 22], resulting in failure to activate the intracellular signaling pathway JAK/STAT [23, 24, 25]. But the mechanism that originally caused CD4 T cells to become anergic had long remained unknown.

In a study published by Pr. Thèze’s group in 2020, the scientists examined dysfunctional CD4 T cells by stimulated emission depletion microscopy and showed that over 80% of resting cells from viremic patients (VP) had a “bumpy” appearance owing to the presence of abnormally large membrane microdomains at their surface (aMMDs). This unusual morphological feature was absent from CD4 T cells in healthy donors (HD) [26]. Upon stimulation with IL-7, bumpy CD4 T cells from VP remained morphologically unchanged and unresponsive. In contrast, HD CD4 T cells rearranged their membrane to display small, physiological membrane microdomains (pMMDs) and responded with activation of the JAK/STAT pathway. Importantly, the receptors of the IL-7 cytokine (IL-7R) were found to become trapped in the aMMDs of CD4 T cells from VP, providing evidence that their functional defects were due to their membrane abnormalities.

The researchers then found that these cellular defects were caused by a circulating enzyme, phospholipase PLA2G1B. In vivo, they showed that PLA2G1B acts in conjunction with a viral protein, gp41, that possibly targets the phospholipase to the surface of CD4 T lymphocytes, where the enzyme digests the lipids that form the cell membrane and causes the membrane defects (Figure 1). The gp41 viral protein acts therefore as a cofactor amplifying the digestion of the membrane by PLA2G1B. Interestingly, a similar mechanism was observed in presence of large amount of enzyme PLA2G1B with or without presence of a gp41 cofactor.

The anti-PLA2G1B antibody should reverse CD4 T cell dysfunctions

To counter the effects of PLA2G1B on CD4 T cells, the researchers developed a mouse monoclonal antibody (mAb) that inhibits the enzymatic activity of the protein. In vitro, the anti-PLA2G1B mAb suppresses PLA2G1B-induced CD4 T cell death and restores CD4 T cell response to cytokine stimulation by IL-7. In vivo, the antibody suppresses the unresponsiveness of CD4 T cells induced by human PLA2G1B injection in mice. Upon humanization, an anti-PLA2G1B mAb named DIACC1010 retained the ability to restore CD4 T cell response to IL-7, becoming a promising immunotherapeutic tool to reverse CD4 anergy in HIV patients, by inhibiting the action of PLA2G1B (Figure 1).

The current treatment of HIV-infected patients consists of antiretroviral therapy (ART), a combination of antiviral drugs that leads to full recovery of CD4 T cell numbers and function in 80% of patients, who display a near to normal life expectancy. However, up to 20% of HIV patients under ART present persistently low counts of CD4 T lymphocytes and are at higher risk of developing other diseases, including cancer. DIACC1010 is a promising treatment, complementary to ART, that could restore CD4 repertoire and function in these patients.

Figure 1: mechanism of action of DIACC1010

Healthy CD4 T cells form physiological membrane microdomains (pMMDs) upon activation with IL-7 and respond by activating JAK/STAT5 signaling. In the presence of pathogen, the PLA2G1B phospholipase acts in concert with a pathogenic peptide (the gp41 cofactor in HIV-infected patients) to induce the formation of abnormal membrane microdomains (aMMDs) which trap surface proteins such as the IL-7 receptor (IL-7R) and block their function. The resulting “bumpy CD4 T cells” become anergic and fail to activate the JAK/STAT5 pathway in response to IL-7 stimulation. A similar mechanism has been observed in presence of large amount of enzyme without presence of a cofactor. Treatment of HIV patients with the anti-PLA2G1B mAb DIACC1010 is expected to block the action of PLA2G1B and restore functionality of CD4 T cells.


DIACC1010 in other pathological contexts and cancers

CD4 T cell anergy has also been observed in other diseases, including cancer. Among other malignancies, CD4 T cell dysfunction was already thought to play an important role in immune evasion of pancreatic cancer cells [27]. In addition, searching for peptides that could act as PLA2G1B cofactors, like gp41 in the case of HIV, Diaccurate scientists found a peptide derived from Porphyromonas gingivalis, an oral pathogen whose presence is highly associated with an increased risk of pancreatic cancer [28]. The researchers then found that plasma from pancreatic cancer patients could render CD4 T cells unresponsive to IL-7 stimulation, an effect that was suppressed using an anti-PLA2G1B mAb. These findings indicate that CD4 T cell activity can be restored in cancer, and support the development of DIACC1010 for the treatment of pancreatic cancer to reestablish active CD4 T cells.

Development strategy

Preclinical studies to characterize DIACC1010 immunopharmacological functions in HIV are currently under way. The company intends to establish a partnership with a leader in the field to confirm the potential of the anti-PLA2G1B immunotherapy mAb in SHIV models (the gold standard for preclinical development in HIV) then in HIV-infected patients.

In 2021, Diaccurate initiated a research program in oncology to validate cancer co-factors, assess PLA2G1B expression profile in different tumors and develop various tools such as surrogate anti-mouse PLA2G1B antibody and mouse models. The objective is to establish an actionable preclinical Proof-of-Concept of DIACC1010 in solid tumors in 2022 and initiate human clinical trials by 2024.


  1. DeNardo, et al. (2009). CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages. Cancer Cell 16, 91–102.
  2. Kerdiles et al., T cell regulation of natural killer cells J Exp Med 2013.
  3. Jost, S et al (2014). CD4+ T-Cell Help Enhances NK Cell Function following Therapeutic HIV-1 Vaccination. Journal of Virology 88, 8349–8354.
  4. Crotty, S. (2011). Follicular Helper CD4 T Cells (TFH). Annu. Rev. Immunol. 29, 621–663.
  5. Tay, R et al. 2020. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. Cancer Gene Therapy, 28(1–2): 5–17.
  6. Jenkins, M. K. et al. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol. Rev. 95, 113–135 (1987).
  7. Kalekar et al. CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors Nat Immunol 2016.
  8. (TB) Zhengang et al, Multifunctional CD4 T Cell Responses in Patients with Active Tuberculosis Nature SR, 2012
  9. (TB) AM Cooper, Cell-mediated immune responses in tuberculosis Ann Rev Immunol, 2009
  10. (SPV) SJ. Glennie et al. Impaired CD4 T Cell Memory Response to Streptococcus pneumoniae Precedes CD4 T Cell Depletion in HIV-Infected Malawian Adults PLoS One, 2011
  11. Ilan J. Zajac et al., J Exp Med, 1998
  12. HBV (T cell anergy): Yuen MF et al. Hepatitis B virus infection Nature Reviews Disease Primers volume 4, 18035 (2018).
  13. HCV (CD4 T cell anergy):  Ulsenheimer A et al. Detection of functionally altered hepatitis C virus-specific CD4+ T cells in acute and chronic hepatitis C Hapathology AASLD 2003
  14. HIV: David D, et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci U S A. 1998;95(19):11348–11353
  15. Février M et al. CD4+ T Cell Depletion in Human Immunodeficiency Virus (HIV) Infection: Role of Apoptosis MDPI 2011
  16. Rodrigues V et al. Impairment of T Cell Function in Parasitic Infections PLOS 2014
  17. (Colorectal cancer) X Sun et al., Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling Oncotarget, 2017 ; (Metastatic cancers) lymphopenia : J Péron et al., CD4 lymphopenia to identify end-of-life metastatic cancer patients Eur J Cancer, 2013 ; (Review T cell anergy) J.Crespo et al., T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment Curr Opin  Immunol, 2013 + DM. Pardoll, The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer, 2012 ; (Pancreatic cancer) P Fogar et al.Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle , Pancreas 2011
  18. Angélique Biancotto  et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008 Jan 15;111(2):699-704.
  19. Bruce Walker, Andrew McMichael The T-cell response to HIV  Cold Spring Harb Perspect Med. 2012 Nov 1;2(11):a007054.
  20. David D, et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci U S A. 1998;95(19):11348–11353.
  21. Colle JH, et al. The correlation between levels of IL-7Ralpha expression and responsive- ness to IL-7 is lost in CD4 lymphocytes from HIV-infected patients. AIDS. 2007;21(1):101–103.
  22. Colle JH, et al. Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lym- phocytes from HIV-infected patients--effects of antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;42(3):277–285.
  23. Landires I, et al. HIV infection perturbs inter- leukin-7 signaling at the step of STAT5 nuclear relocalization. AIDS. 2011;25(15):1843–1853.
  24. Juffroy O, et al. Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/ STAT5 pathway. J Virol. 2010;84(1):96–108.
  25. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
  26. Julien Pothlichet et al. PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. J Clin Invest. 2020 Jun 1;130(6):2872-2887.
  27. Paola Fogar et al. Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle. Pancreas. 2011 Oct;40(7):1131-7.
  28. Fan X, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018 Jan;67(1):120-127.